

## **EXHIBIT D**

# USPTO PATENT FULL-TEXT AND IMAGE DATABASE

[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[Bottom](#)[View Cart](#)

*Searching US Patent Collection...*

**Results of Search in US Patent Collection db for:**  
**SPEC/"transdermal delivery device": 314 patents.**

*Hits 1 through 50 out of 314*

[Next 50 Hits](#)[Jump To](#)[Refine Search](#)

PAT. NO.	Title
1 <a href="#">7,364,742</a>	<a href="#">T RSV proteins, antibodies, compositions, methods and uses</a>
2 <a href="#">7,363,075</a>	<a href="#">T Transdermal delivery system for dried particulate or lyophilized medications</a>
3 <a href="#">7,335,377</a>	<a href="#">T Transdermal delivery system for dried particulate or lyophilized medications</a>
4 <a href="#">7,323,191</a>	<a href="#">T Transdermal warfarin system</a>
5 <a href="#">7,312,236</a>	<a href="#">T Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-HT.sub.1F agonists</a>
6 <a href="#">7,291,721</a>	<a href="#">T Anti-IL-6 antibodies, compositions, methods and uses</a>
7 <a href="#">7,291,632</a>	<a href="#">T Substituted 2-carboxylamino-6-piperidinaminopyridines and substituted 1-carboxylamino-3-piperidinaminobenzenes as 5-HT.sub.1F agonists</a>
8 <a href="#">7,273,619</a>	<a href="#">T Transdermal composition of an antiemetic agent</a>
9 <a href="#">7,270,830</a>	<a href="#">T Transdermal buprenorphine dosage regimen for analgesia</a>
10 <a href="#">7,252,971</a>	<a href="#">T IL-23p40 specific immunoglobulin derived proteins</a>
11 <a href="#">7,247,711</a>	<a href="#">T IL-23p40 specific antibody</a>
12 <a href="#">7,241,733</a>	<a href="#">T Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses</a>

- 13 [7,229,645](#) [T Spray freeze-dried compositions](#)
- 14 [7,226,910](#) [T Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists](#)
- 15 [RE39,588](#) [T Transdermal drug delivery device](#)
- 16 [7,196,074](#) [T Methods of making, using and pharmaceutical formulations comprising 7.alpha., 11.beta.-dimethyl-17.beta.-hydroxyestra-4, 14-dien-3-one and 17 esters thereof](#)
- 17 [7,184,826](#) [T Device and method for enhancing transdermal flux of agents being delivered or sampled](#)
- 18 [7,182,955](#) [T Abuse-resistant transdermal dosage form](#)
- 19 [7,172,859](#) [T System and method for optimizing tissue barrier transfer of compounds](#)
- 20 [7,166,625](#) [T Method for treating fibrotic diseases and other indications](#)
- 21 [7,133,717](#) [T Tissue electroporation for enhanced drug delivery and diagnostic sampling](#)
- 22 [7,113,821](#) [T Tissue electroporation for enhanced drug delivery](#)
- 23 [7,105,685](#) [T Cannabinol derivatives](#)
- 24 [7,097,853](#) [T Matrix for transdermal drug delivery](#)
- 25 [7,087,240](#) [T Device and method for the treatment of erectile dysfunction](#)
- 26 [7,087,035](#) [T Device and method for enhancing skin piercing by microprotrusions](#)
- 27 [7,084,261](#) [T Pegylated T1249 polypeptide](#)
- 28 [7,084,150](#) [T Analogs and prodrugs of buprenorphine](#)
- 29 [7,083,781](#) [T Film forming polymers, methods of use, and devices and applications thereof](#)
- 30 [7,078,425](#) [T Preparation of phosphatase inhibitors](#)
- 31 [7,078,396](#) [T Method of treating disorder related to high cholesterol concentration](#)
- 32 [7,070,786](#) [T RSV proteins, antibodies, compositions, methods and uses](#)
- 33 [7,049,415](#) [T Pegylated T20 polypeptide](#)
- 34 [7,045,145](#) [T Transdermal contraceptive delivery system and process](#)
- 35 [7,022,313](#) [T Hydrogel particle formulation](#)
- 36 [7,019,024](#) [T Pharmaceutical for treatment of neurological and neuropsychiatric disorders](#)
- 37 [7,018,649](#) [T Felodipine transdermal device and methods](#)
- 38 [7,011,844](#) [T Formulations for the administration of fluoxetine](#)
- 39 [6,979,675](#) [T Treatment of cancer with 2-deoxyglucose](#)
- 40 [6,960,353](#) [T Formulations for the transdermal administration of fenoldopam](#)
- 41 [6,960,193](#) [T Method and apparatus for the transdermal administration of a](#)

substance

- 42 6,921,530 **T** Low dose IL-2 for potentiation of immunity
- 43 6,918,901 **T** Device and method for enhancing transdermal agent flux
- 44 6,908,760 **T** Raised surface assay plate
- 45 6,908,448 **T** Substance delivery device
- 46 6,893,664 **T** Particle delivery techniques
- 47 6,893,656 **T** Athletic patch
- 48 6,893,655 **T** Transdermal delivery devices
- 49 6,855,133 **T** Transdermal perfusion of fluids
- 50 6,852,526 **T** Transdermal assay with magnetic clamp
- 

[Next List](#)

[Top](#)

[View Cart](#)

[Home](#)

[Quick](#)

[Advanced](#)

[Pat Num](#)

[Help](#)